To prolong the survival and development of advanced melanoma, the two drugs

U.S. researchers have developed two new drugs can be extended with advanced melanoma, which is announced on Sunday the lives of patients.

 

Research on two drugs, presented at the ongoing annual meeting of American Society of Clinical Oncology in Chicago, according to health news.

 

This is the first time in the treatment of melanoma, the big news, skin cancer, one is notoriously difficult to treat, let alone a fatal one form of healing, the report said.

 

The first treatment, vemurafenib, suppressor gene mutation in all melanoma patients harboring half, but had not been U.S. Food and Drug Administration approval.

 

Other drugs, Yervoy (ipilumumab), is an immune system treatment, to win approval in March.

 

"U.S. FDA approval in March ipilumumab (Yervoy) is the first new drug approved for melanoma in 13 years, said:" Melanoma Research Foundation executive director.

 

This is in commemoration of the two drugs Sloan - Kettering Cancer Center researchers in New York City development, the report said.

 

"This is really a personalized service to a huge step in melanoma," Dr. Paul Chapman, the first major of study and melanoma / in the Memorial Sloan - Kettering sarcoma service attending physician, said in a statement. "This (vemurafenib) was the first successful treatment for melanoma patients who carry mutations in the tumor-specific, and may eventually become the only two drugs available that can improve the overall survival of advanced cancer."

 

"There are two trials to set the first line shows the survival in melanoma patients in the interests of the two - we're not just here a few years ago," said Dr. Stephen Hodi, Director of the Centre at the Dana Farber Cancer melanoma Institute Boston. "This is a huge, fundamental shift in the results of the field."

 

In the trial by the drug manufacturers vemurafenib sponsorship, the researchers randomly assigned advanced, inoperable 675 melanoma, dacarbazine chemotherapy drugs or vemurafenib. Vemurafenib BRAF gene V600E mutation in the target.

 

In the three-month mark, patients taking vemurafenib 63 and 74 percent less likely to die percent less likely to die of cancer or to see their return, taking more than dacarbazine alone.

 

Few patients had side effects in vemurafenib group, but some people develop squamous cell carcinoma, less risk of skin cancer forms.

 

This is the first drug, has proven to be difficult in this group than in patients treated with chemotherapy, the researchers said.

 

"There is such a huge benefit, we recommend the patient over," Chapman said in a news conference on Sunday. "This is unprecedented this early trial reports. The median follow-up time was three months." However, the difference between the two groups became apparent almost immediately.

 

Bo Shilin Schuchter, a common blood, Abramson Cancer Center at the University of Pennsylvania in Philadelphia, head of oncology and host the briefing, said some patients the symptoms disappeared almost immediately, so that they can reduce the pain medicine, in just 72 hours.

 

"The median time to progression and dacarbazine with three vemurafenib, this is a huge difference between 1.6 months and months," Chapman said.

 

In the second study, about 500 randomly selected patients receiving Yervoy Jakarta Kabbah hydrochloride or dacarbazine alone.

 

Take these two drugs lead than the average 11.2 months to 9.1 months for dacarbazine alone. The time of relapse is about the same two groups: 2.8 months and 2.6 months.

 

Almost half of the joint is still alive one year after treatment, while another group of 36.3 percent. Two years later, the rates were 28.5 percent and 17.9 percent, respectively.

 

Three years, 20.8 percent of the combined group is still alive, compared with 12.2 percent of those taking chemotherapy alone.

 

This is the first study combining chemotherapy and immunotherapy are safe and effective.

 

A combination of testing and Yervoy vemurafenib has already begun, according to health news.